Bobby Sheng, Bora Pharmaceuticals CEO

With new ac­qui­si­tion, Bo­ra to ven­ture in­to bi­o­log­ics

Last week, Tai­wan-based CD­MO Bo­ra Phar­ma­ceu­ti­cals an­nounced that it ac­quired Eden Bi­o­log­ics. Now, it says that pur­chase has helped es­tab­lished Bo­ra Bi­o­log­ics, ex­pand­ing in­to the bio­phar­ma­ceu­ti­cal mar­ket.

The ac­qui­si­tion of the com­pa­ny’s as­sets, which are lo­cat­ed in the Hsinchu Bio­med­ical Sci­ence Park in Tai­wan, is help­ing Bo­ra build its pres­ence in the bio­phar­ma world by ex­pand­ing pro­duc­tion ca­pac­i­ty of cell lines for the pro­duc­tion of pro­tein drugs. It will al­so im­prove the qual­i­ty con­trol and in­spec­tion spec­i­fi­ca­tions, as well as cell bank gen­er­a­tion. The fa­cil­i­ty has four 500-liter biore­ac­tors that have been ap­proved by Eu­ro­pean and Tai­wanese reg­u­la­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.